CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients
详细信息 查看全文
- 作者：Cong Li (1) (2)
Zhimin Wang (3)
Fangqi Liu (1) (2)
Ji Zhu (2) (4)
Li Yang (1) (2)
Guoxiang Cai (1) (2)
Zhen Zhang (2) (4)
Wei Huang (3)
Sanjun Cai (1) (2)
Ye Xu (1) (2) - 关键词：CXCL10 ; Neoadjuvant chemoradiotherapy ; Rectal cancer ; Angiogenesis
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：October 2014
- 年：2014
- 卷：35
- 期：10
- 页码：9683-9691
- 全文大小：660 KB
- 参考文献：1. Dedemadi G, Wexner SD. Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate? Dig Dis. 2012;30 Suppl 2:109-7. CrossRef
2. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, et al. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol. 2012;40:560-.
3. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 2007;67:3396-05. CrossRef
4. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep. 2010;37:3029-6. CrossRef
5. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44:1027-8. CrossRef
6. Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 2011;18:2461-. CrossRef
7. Jao SW, Chen SF, Lin YS, Chang YC, Lee TY, Wu CC, et al. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol. 2012;19:3432-0. CrossRef
8. Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini M, Digito M, et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvantchemoradiotherapy. Ann Surg Oncol. 2012;19:3089-6. CrossRef
9. Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett. 2008;272:221-. CrossRef
10. Kim J, Kim J, Li S, Yoon W, Song K, Kim K, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:195-00. CrossRef
11. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, et al. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics. 2011;8:87-2.
12. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, et al. Microarray-based prediction of tumor response to neoadjuvantradiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol. 2008;6:53-1. CrossRef
13. Casado E, Moreno Garcia V, Javier Sanchez J, Blanco M, Maurel J, Feliu J, et al. A combined strategy of SAGE and quantitative PCR provides a 13-Gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res. 2011;17:4145-4. CrossRef
14. Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ, Turner T. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS One. 2012;7:e40812. CrossRef
15. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, et al. Expression of IP-10 related to angiogenesis in u - 作者单位：Cong Li (1) (2)
Zhimin Wang (3)
Fangqi Liu (1) (2)
Ji Zhu (2) (4)
Li Yang (1) (2)
Guoxiang Cai (1) (2)
Zhen Zhang (2) (4)
Wei Huang (3)
Sanjun Cai (1) (2)
Ye Xu (1) (2)
1. Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai, 200032, China
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
3. Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Academy of Science & Technology, Bibo road, 250, Shanghai, 201203, China
4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai, 200032, China - ISSN：1423-0380
文摘
Chemoradiotherapy has been commonly used as neoadjuvant therapy for rectal cancer to allow for less aggressive surgical approaches and to improve quality of life. In cancer, it has been reported that CXCL10 has an anti-tumor function. However, the association between CXCL10 and chemoradiosensitivity has not been fully investigated. We performed this study to investigate the relationship between CXCL10 expression and chemoradiosensitivity in rectal cancer patients. Ninety-five patients with rectal cancer who received neoadjuvant chemoradiotherapy (NCRT) were included. Clinical parameters were compared with the outcome of NCRT and CXCL10 messenger RNA (mRNA) expression between the pathological complete response (pCR) group and non-pathological complete response (npCR) group. CXCL10 mRNA and protein expressions between groups were analyzed using the Student’s t test and chi-square test. The mean mRNA level of CXCL10 in the pCR group was significantly higher than that in the npCR group (p--.010). In the pCR group, 73.7?% of the patients had high CXCL10 mRNA expression, and 61.4?% of the patients in the npCR group had low CXCL10 mRNA expression. Subjects with high CXCL10 mRNA expression demonstrated a higher sensitivity to NCRT (p--.011). The receiver operating characteristic curve showed that the diagnostic performance of CXCL10 mRNA expression had an area under the curve of 0.720 (95?% confidence interval, 0.573-.867). There were no differences between the pCR and npCR groups in CXCL10 protein expression (p--.05). High CXCL10 mRNA expression is associated with a better tumor response to NCRT in rectal cancer patients and may predict the outcome of NCRT in this malignancy.